Bortezomib biosimilar - Dr. Reddy's Laboratories

Drug Profile

Bortezomib biosimilar - Dr. Reddy's Laboratories

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Multiple myeloma

Most Recent Events

  • 31 Aug 2016 Suspended - Clinical-Phase-Unknown for Multiple myeloma (First-line therapy, Late-stage disease) in India (Injection)
  • 20 May 2015 Clinical trials in Multiple myeloma (First-line therapy, Late-stage disease) in India (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top